

Uniform PDL Management Guidance

Due to numerous and unexpected changes in drug availability at the state and federal level, the Drug Formulary Committee recommends DHS manages the Uniform PDL in a timely manner according to the following guidelines:

When a drug listed on the Uniform PDL is discontinued, the following steps are recommended:

1. If the drug is nonpreferred, remove the drug from the Uniform PDL.
2. If the drug is multisource and preferred, remove the drug from the Uniform PDL and consider preferring the nonpreferred brand or generic formulation as a replacement if the discontinuation will result in 1 or fewer preferred drugs on the Uniform PDL.
3. If preferring the nonpreferred brand or generic formulation is not feasible, or the discontinued drug is single source, consider preferring an alternative with same or similar mechanism of action or a different dosage form with the same active ingredient as the discontinued drug.
4. If preferring an alternative drug with the same or similar mechanism of action, or different dosage form with the same active ingredient, is not possible, consider preferring an alternative drug within the PDL therapeutic class.
5. If a drug is moved from nonpreferred status to preferred status, DHS is to inform the DFC of the action taken at a next DFC meeting.

DFC review: 4/17/2024